Kirsten Carlson
Plus aucun poste en cours
Profil
Kirsten Carlson worked as Vice President-Urology at Avadel Pharmaceuticals Plc, Vice President-Marketing at Pear Therapeutics, Inc., and Vice President-Marketing & Market Access at Tolmar Pharmaceuticals, Inc. She obtained an undergraduate degree from the University of Rhode Island.
Anciens postes connus de Kirsten Carlson
| Sociétés | Poste | Fin |
|---|---|---|
| PEAR THERAPEUTICS, INC. | Sales & Marketing | 01/08/2022 |
| Tolmar Pharmaceuticals, Inc. | Sales & Marketing | - |
| AVADEL PHARMACEUTICALS PLC | Corporate Officer/Principal | - |
Formation de Kirsten Carlson
| University of Rhode Island | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AVADEL PHARMACEUTICALS PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Pear Therapeutics, Inc.
 Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |
| Tolmar Pharmaceuticals, Inc. |
